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Abstract
Since the discovery of the gene associated with cystic
fibrosis (CF), there has been tremendous progress in
the care of patients with this disease. New therapies
have entered the market and are part of the standard
treatment of patients with CF, and have been
associated with marked improvement in survival. Now
there are even more promising therapies directed at
different components of the pathophysiology of this
disease. In this review, our current knowledge of the
pathophysiology of lung disease in patients with CF is
described, along with the current treatment of CF
lung disease, and the therapies in development that
offer great promise to our patients.
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Introduction
Cystic fibrosis (CF) is a genetic disease resulting in compli-
cations in multiple organs, but especially involving the
lungs and pancreas. CF is associated with considerable
morbidity and an early demise, although the last two dec-
ades have realized a remarkable improvement in health
and survival such that the median age of predicted survival
now approaches 40 years [1]. This is the result of a combi-
nation of factors including the development of a sophisti-
cated comprehensive care network and the use of several
new medications developed specifically for the treatment
of CF-related disease. This is a review of the current state
of the treatment of CF lung disease and a look to the
future development of promising treatment options.
Pathophysiology of disease in cystic fibrosis
CF is an autosomal recessive disease resulting from the
inheritance of a mutant allele of the gene for cystic fibrosis
transmembrane conductance regulator (CFTR) from each
parent [2-4]. CFTR is a c-AMP-regulated anion channel
normally expressed on the apical surfaces of specialized
epithelial cells, including those of the sweat glands, pan-
creas, and gastrointestinal and reproductive tracts, as well
as airway epithelia and submucosal glands [5,6]. Although
the transport of chloride ions across membranes is a
recognized and critical CFTR function [6], there are other
proposed CFTR-mediated effects, such as transport of
bicarbonate [7]. Inheritance of mutant CFTR alleles is
accompanied by a qualitative and/or quantitative reduc-
tion of CFTR activity at the cell surface; the extent to
which CFTR activity is reduced influences the diversity
and severity of pathophysiologic sequelae associated with
CF [6]. Individuals carrying a single CFTR mutation may
retain as little as 50% of wild-type CFTR activity but are
unaffected. Persons with CF (that is, carrying two mutant
CFTR alleles) in which one mutation retains residual (but
reduced) CFTR function have less aggressive disease phe-
notypes and better overall survival than their peers who
carry mutations in which very little or no CFTR activity is
retained [6].
Pathophysiologic manifestations of CF arise in several
organ systems in utero. Neonates with CF are identified
for further screening evaluation in part based upon ele-
vated levels of circulating immunoreactive trypsinogen
caused by pancreatic ductile or duct blockage, pancreatic
autodigestion, and leakage of digestive enzymes into the
systemic circulation [8]. From birth, reduced CFTR activ-
ity in the sweat glands of people with CF hampers that
individual’s ability to recover salt from their sweat [6].
This provides the basis for the definitive test for CF: pilo-
carpine-induced iontophoresis (the CF ‘sweat test’), with
the majority of patients having chloride concentrations in
sweat exceeding 60 mEq/L [8]. Reduced water and bicar-
bonate secretion in the gut may lead to meconium ileus in
10% to 15% of CF neonates [6]. Finally, most, if not all,
males with CF are born without a palpable vas deferens
[6].
Organ systems pathologies persist and evolve after
birth. More than 90% of infants with CF lose all exocrine
* Correspondence: flumepa@musc.edu
1Medical University of South Carolina, Charleston, SC, USA
Full list of author information is available at the end of the article
Flume and Van Devanter BMC Medicine 2012, 10:88
http://www.biomedcentral.com/1741-7015/10/88
© 2012 Flume and Van Devanter; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
pancreatic function and experience a lifetime of pancrea-
tic insufficiency [6]. The risk of CF-related diabetes melli-
tus increases with age, occurring in more than a quarter
of individuals 25 years of age and older [1]. Gastrointest-
inal complications continue, with individuals experien-
cing fat and fat-soluble vitamin malabsorption and
associated steatorrhea, poor growth, increased risk of
gallstones and hepatobiliary disease [6]. Interestingly, the
organ system that currently accounts for the greatest per-
centage of premature deaths from CF, the respiratory sys-
tem, appears essentially normal at birth. Of course,
respiration only begins at birth, and complications arising
from reduced CFTR activity in the sinuses and respira-
tory tract can become apparent remarkably soon after
[9-16]. A summary of the pathophysiology in the lung is
shown in Figure 1. Reduced CFTR activity results in
volume depletion of the lung apical surface liquid (ASL),
leading to increased adhesiveness and cohesiveness of
airway phlegm, effectively plugging the small airways
[17]. This obstruction, and associated neutrophilic
inflammation, can be identified as air trapping and bron-
chial wall thickening using high-resolution computerized
tomography [14,15]. Bacterial opportunists enter the
upper and lower respiratory tract by inhalation or aspira-
tion, from where it is not possible to clear them; their
growth and expansion leads to local inflammation [9-12].
Very early, this triad of chronic obstruction, infection
and inflammation sets in motion a lifelong degradation
of lung anatomy and function [6,16,18,19], ultimately
contributing to the untimely deaths of persons with CF;
respiratory failure accounts for >80% of mortality in CF
[1].
The relationship of chronic cystic fibrosis
therapies to underlying pathophysiology
Chronic management of CF today is focused primarily on
the mitigation of downstream pathologies that accumu-
late due to reduced CFTR activity in the digestive and
respiratory systems. Pancreatic insufficiency and poor
absorption of fat and fat-soluble vitamins are reasonably
Figure 1 Therapeutic targets of cystic fibrosis respiratory therapies. Physiological ramifications of reduced CFTR activity in the lungs of
patients with cystic fibrosis are highlighted by large gray arrows. Therapeutic classes that have been and/or are being investigated for the
chronic management of cystic fibrosis lung disease are shown in light gray boxes. Despite different mechanisms of action, all share the goal of
reducing lung disease damage caused by the interplay of obstruction, infection, and inflammation. Reprinted with permission from VanDevanter
DR, Konstan MW: Outcome measures for clinical trials assessing treatment of cystic fibrosis lung disease. Clinical Investigation 2012; 2(2):163-175
[152].
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well-managed by pancreatic enzyme supplementation at
every meal, consumption of a high fat and high calorie
diet, and vitamin supplementation [20]. Careful attention
to patient nutrition has produced dramatic improve-
ments in nutritional status and has contributed to
improved overall health for all ages of patients with CF
[1]. Gastrointestinal tract obstruction, experienced by
about 25% of adults with CF in their lifetime, is treated
both pharmacologically and surgically [6]. Chronic pul-
monary therapies target the movement of tenacious
phlegm out of the respiratory tract, suppression of
chronic bacterial infection and reduction of chronic local
inflammation. Surgical intervention is also an important
component of respiratory tract management, being com-
mon for removal of sinus polyps [21], in rare cases to
arrest hemoptysis [22] and, for those with end-stage
bronchiectasis, bilateral lung transplantation [23].
A primary complication of CF is the accumulation of
airway phlegm that contains almost no intact mucin and
consists predominantly of bacteria, inflammatory cells,
polymeric DNA and F-actin, with characteristics more
similar to pus than mucus. A variety of chest phy-
siotherapies are recommended for improving clearance
of airway phlegm [24]. These therapies can be combined
with medications that might alter the airway phlegm,
making them easier to clear from the airways.
Growth and expansion of inhaled or aspirated bacter-
ial opportunists within the airway of patients with CF
are treated with antibiotics in four distinct modalities:
chronic prophylaxis to avoid (specific) bacterial infec-
tion; conversion to culture negativity upon detection of
new (specific) bacterial opportunists; palliation of acutely
elevated signs and symptoms of infection; and chronic
suppression of established infections. CF antibiotic treat-
ment modalities have evolved over years of trial and
error, some without strong objective evidence of clinical
benefit, and have features that range from the uncom-
mon to the heretical when compared with the antibiotic
management of systemic bacterial infections. Manage-
ment of increased respiratory signs and symptoms
(loosely defined as pulmonary exacerbations) routinely
includes antibiotic treatment [25]. Although exacerba-
tions treated with intravenous antibiotics have tended to
receive the most attention from epidemiologists [26-32]
and drug developers [33-37], they appear to constitute a
minority of acute, antibiotic-treated events, particularly
in younger patients [38]. Surprisingly, although tens of
thousands of these events occur annually and they have
been associated with decreased quality of life [39-41],
accelerated lung function decline [27,28] and increased
mortality risk [42-45], little objective evidence of the
benefit of antibiotic treatment is available and important
questions as to optimal antibiotic treatment of exacerba-
tions remain [46].
Local airway inflammation is accepted as a critical dri-
ver of lung disease progression and death [6], but thera-
pies directly targeting local inflammation have been
slow to achieve widespread use [47], in part because of
the concern over treatment-associated adverse events.
Interventions more directly targeting the cystic
fibrosis defect
CF disease sequelae arise from reduced CFTR function in
disparate tissues, and it follows that the most compre-
hensive and effective treatment of CF would be reconsti-
tution or supplementation of CFTR activity prior to the
establishment of irreversible functional and structural
damage. Substantial progress has been made toward this
very approach, but with important limitations. As noted
above, multiple pathophysiologic consequences of
reduced CFTR arise in utero, necessitating downstream
management of subsequent disease sequelae even in very
young infants with CF. For example, fibrosis of the exo-
crine pancreas, when it occurs, is likely nearly complete
at birth and reconstitution of CFTR function in the pan-
creas of neonates is unlikely to lead to pancreatic suffi-
ciency later in life. However, the observation that the
respiratory tract is, by comparison, relatively unaffected
at birth suggests that reconstitution or supplementation
of CFTR activity in the airway in infants with CF may
have a dramatic effect on lung disease progression.
Current and future therapies
Now that we have outlined the general approaches to the
various aspects of the pathophysiology of CF lung dis-
ease, we can review the details of specific therapies that
are currently in use, or are in active stages of develop-
ment, and could be realized as approved therapies in the
near future. These are addressed in the general order of
the pathophysiologic mechanisms (Figure 1).
CFTR correction
Shortly after identification of the CFTR gene, there was
particular interest in and hope that insertion of a normal
copy of the gene (that is, gene therapy) would restore
CFTR function in persons with CF [5]. Gene therapy has
long been promised as the pathway to a cure for CF and
an assumed advantage of gene therapy for CF was that
the airways should present a relatively easy target to
reach. However, much has been learned from gene ther-
apy trials and the airways present many barriers to suc-
cessful gene therapy, more so than many other organs.
The reader is referred to a recent review of the status of
CF gene therapy investigations [48], but what has been
demonstrated is that the principle of transfer of the
CFTR gene is possible and that a partial correction of the
basic defect in the airways of patients with CF can be
achieved without major safety issues. What has yet to be
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demonstrated is that CFTR gene transfer to the lung will
result in a clinical benefit and whether gene transfer and/
or expression can be successfully repeated over what
would be decades of treatment. The UK Cystic Fibrosis
Gene Therapy Consortium is planning to initiate a multi-
dose clinical trial of gene therapy in 2012, which will be
the first opportunity to find out if gene therapy can result
in clinical benefit.
CFTR modulation
Although we cannot currently supplement mutant CFTR
alleles with a normal copy by gene therapy, small mole-
cules have been identified that can modulate mutant
CFTR protein such that its function may be closer to nor-
malcy. There are more than 1,800 CF gene mutations
that have been identified, but not all are known to cause
disease, allowing for some patients to have minimal
symptoms yet believed to have CF. For those mutations
known to cause complications of CF, we categorize them
based upon the major presumed defect (that is, synthesis,
processing, regulation and channel conductance) [49,50],
but these categories are not highly specific and there is
considerable overlap for some mutations (that is, they
could be sorted into more than one category). The gen-
eral approach to evaluating CFTR-modulating drugs is to
assess their ability to either increase the quantity of
CFTR at the cell surface and/or increase the function of
CFTR.
The first approved CFTR modulator, ivacaftor, is indi-
cated for patients with CF with a specific mutation,
G551D. This mutation results in a reduced probability of
opening of the CFTR channel (an altered gating mechan-
ism); there is a sufficient quantity of CFTR but there is
impaired function of the channel [51]. Ivacaftor potenti-
ates the CFTR channel by increasing the probability of
channel opening [51]. A clinical trial in patients with CF
with at least one copy of G551D demonstrated proof of
this concept with a decrease in mean sweat chloride from
approximately 100 mEq/L to approximately 51 mEq/L
[52]. More importantly, there were remarkable clinical
benefits with an increase in forced expiratory volume in
one second by 10.6% of predicted value, a reduction in
risk of pulmonary exacerbations by 55%, an increase in
weight and an improvement in quality of life [52]. Similar
results have been demonstrated in pediatric patients and
ivacaftor has been approved by the Food and Drug
Administration (FDA) for patients aged six years and
above. There are important questions that remain to be
answered, including whether the drug be used in newly
diagnosed infants, will the drug work in other mutations
(especially gating mutations), and will the drug have an
effect on other manifestations of disease (for example,
sinus disease, gastrointestinal absorption, reduction in
inflammation in the airways)?
Studies that address the first question should easily be
able to demonstrate an effect on sweat chloride and any
new safety issues but other clinical benefits will be more
challenging; is it possible that sweat chloride could serve
as an acceptable surrogate clinical endpoint? As to the
second question, we know that ivacaftor will not be an
effective therapy alone in patients homozygous for
F508del CFTR mutations [53]. This is not an unexpected
finding as the F508del mutation results in abnormal pro-
cessing of the CFTR protein such that there is a marked
reduction in the quantity of CFTR at the cell surface
[54,55]. However, it is likely that ivacaftor will potentiate
F508del protein [56], so if the quantity of F508del protein
could be increased at the cell surface by a small molecule,
there is the possibility that ivacaftor could be used in
combination with it to increase CFTR activity. There are
promising agents that may allow for correction of the
CFTR processing defect seen with F508del mutations,
including VX-809 [57] and VX-661 [58]. These are cur-
rently under investigation in combination with ivacaftor
in patients with F508del mutations [59,60]. The last ques-
tion is being addressed in an observational study of
ivacaftor in patients with G551D (the GOAL study) spon-
sored by the Cystic Fibrosis Foundation [61]. This pro-
vides an opportunity to understand the biology of CFTR
modulation, including the direct and indirect effects of
activating CFTR-dependent anion secretion by collecting
specimens and clinical data on a large number of patients
both before and after they begin treatment with ivacaftor.
A specific type of mutation called a nonsense (prema-
ture stop codon) mutation also results in a reduction in
the quantity of CFTR protein at the cell surface. These
mutations, affecting approximately 10% of patients with
CF, prematurely halt translation of mRNA to protein,
resulting in incomplete CFTR proteins [62]. The strategy
necessary to address this problem would require ‘reading
through’ the mutation to the normal stop codon. Ataluren
is an orally delivered investigational drug that has the
potential to overcome the effects of the nonsense mutation
and has been shown to induce the production of full-
length functional CFTR protein at epithelial cell surfaces
in mice [63] and humans [64]. Short-term studies of atalu-
ren in pediatric [64] and adult [65] patients have shown
treatment-induced improvements in CFTR-mediated
chloride transport in respiratory epithelium. A Phase III
clinical trial is currently under investigation in adult and
pediatric patients [66].
Alternate channels
CFTR is not the only channel on the epithelial cell sur-
face responsible for the maintenance of the airway sur-
face liquid. There are other chloride channels including a
calcium-dependent chloride channel [67] and the P2Y
receptor activated by ATP [68]. Early studies of uridine-5
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triphosphate, an analog of ATP, found its short half-life
limited its clinical value [69]. A subsequent analog, denu-
fosol, showed greater stability and early trials held great
promise. A Phase III study (the Transport of Ions to
Generate Epithelial Rehydration study (TIGER1)) demon-
strated lung function improvement [70]; however, a
second placebo-controlled study (TIGER2) did not dupli-
cate these results and further development for CF was
discontinued [71]. Denufosol was observed to have a rela-
tively short half-life (17 minutes) in a pharmacokinetic
sub-study, much shorter than had been predicted from in
vitro and ex vivo studies [72], and it may be that study
failure was due to simple pharmacokinetics. It is also pos-
sible that agents such as denufosol may be capable of
changing the rate of lung function decline without neces-
sarily improving lung function, in which case the choice
of lung function improvement as the primary efficacy
endpoint in the denufosol studies was problematic.
Lancovutide increases intracellular calcium level and
activates an alternative chloride channel [73]. A proof-of-
concept clinical study showed promise with increased
chloride conductance, as measured by nasal potential dif-
ference, when applied topically to nasal epithelium in
patients with CF [74], and a small, single-center clinical
trial in 24 patients with CF found that it was safe and ben-
efitted pulmonary function [75]. However, there has been
no further development of this drug in clinical trials.
One of the roles of CFTR is to inhibit sodium absorp-
tion and its absence causes excessive sodium (and water)
absorption through an epithelial sodium channel [76]. An
alternative approach to CFTR treatment could be to inhi-
bit sodium absorption through the epithelial sodium chan-
nel. Aerosolized amiloride (an epithelial sodium channel
blocker with a short half-life) not only had no clinical ben-
efit, it showed a trend toward poorer lung function in the
treated patients [77]. There may yet be other channels
identified as more relevant in CF lung disease, or agents
with a longer half-life may be a better option.
Hydrators
Another proposed approach to restoring airway surface
liquid is the direct instillation of salt and water. This has
been demonstrated to increase the volume of airway sur-
face liquid in cultured CF airway epithelia [78] and it has
been suggested that inhalation of hypertonic saline can
improve mucociliary clearance in vivo [79]. In this latter
study, the benefit occurred in the first 60 minutes [79],
suggesting either that the increase in mucociliary clear-
ance is a short-lived effect or it is the result of another
mechanism, such as transiently increasing the volume of
ASL, unbinding secretions from the airway surface and
inducing cough. In any case, aerosolized hypertonic sal-
ine has demonstrated other clinical benefits. Twice daily
inhalation of hypertonic (7% to 8%) saline has been
shown to improve ventilation inhomogeneity in patients
with CF with ‘normal’ spirometry [80]; reduce sputum
markers of inflammation [81]; reduce the risk of
pulmonary exacerbation [36,82]; and modestly improve
pulmonary function [36,83]. Dose frequency [78] and
concentration [84] may affect the magnitude of the
inhaled hypertonic saline response. Recently, a large ran-
domized placebo-controlled multicenter 48-week study
of inhaled hypertonic saline in children with CF under
six years of age failed to demonstrate a treatment-related
reduction in the rate of pulmonary exacerbation [85].
There has yet to be a definitive demonstration that inha-
lation of lower saline concentrations (commonly pre-
scribed to increase tolerance and adherence) provide
clinical benefit [84].
The challenges of hypertonic saline include poor toler-
ance because of increased cough and bronchospasm [36]
and the time it takes for aerosolization, adding to the
patient’s treatment burden. As stated earlier, the benefit of
aerosolized hypertonic saline occurs early and could be
related to the short time that the drug can affect the
phlegm because of rapid absorption. An alternative
approach is to deliver an osmotic agent to the airways that
could draw water into the airway surface liquid and have a
longer presence for which it to be active. Recently, a dry
powder formulation of mannitol for inhalation has been
developed that presumably shares the inhaled hypertonic
saline mechanism(s), and it has been studied in both CF
and non-CF bronchiectasis. Similar to the data for hyper-
tonic saline, the improvement in airway clearance also
appears to occur in the first 45 minutes, after which the
rate of clearance appears to be the same in all doses tested
[86]. Clinical trials of inhaled mannitol resulted in
improved lung function and a trend to reduced rates of
pulmonary exacerbations; these results seemed to be sus-
tained in an open-label extension of the study [87]. The
drug is currently under review by the FDA. As with hyper-
tonic saline, a substantial minority of patients with CF is
intolerant to this therapy, with cough being a frequently
observed adverse event [87].
Xylitol is another sugar with low transepithelial perme-
ability that may function as an osmolar agent similar to
mannitol. Early studies have demonstrated safety in mice,
healthy volunteers and stable patients with CF when admi-
nistered over a single day [88]. Ongoing clinical trials will
investigate the safety and efficacy of inhaled xylitol com-
pared with hypertonic saline [89].
Airway clearance therapies
Mechanical clearance of phlegm from the airways is one
of the primary therapies for CF airways disease. Because
there is impaired mucociliary clearance, the patient is
dependent upon cough clearance to rid the airways of the
infectious and inflammatory material accumulating in the
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airways. There are several accepted methods of airway
clearance, and guidelines published by the Cystic Fibrosis
Foundation Pulmonary Guidelines Committee offer sev-
eral specific recommendations [24], which can be sum-
marized as follows:
1. some form of airway clearance therapy should be
performed in all patients on a routine basis;
2. no single method of airway clearance therapy has
been proven superior to any other, but this does not
mean they are equivalent in all patients;
3. because of the previous recommendation, there
should be a strategy of determining which therapy
works best for each patient;
4. exercise is a great addition to the airway clearance
regimen.
It is unlikely that there will be any new trials that will
compare these therapies (or new versions) to determine
superiority. The best strategy is to use an algorithm by
which all therapies are introduced to patients at an
appropriate age to determine which will be used and
which will be the most effective [90].
Dornase alfa
Medications have been used to alter the properties of air-
way phlegm to make it easier to clear from the airways.
Both hypertonic saline and mannitol have been demon-
strated to alter the properties of sputum and this may be
an important component of their clinical benefit [86,91].
Recombinant human DNase (dornase alfa) has been devel-
oped to cleave high molecular weight DNA released by
dead neutrophils that contributes to the tenacity of airway
phlegm [92]. Daily inhalation of aerosolized dornase alfa
can reverse early air trapping [93] and ventilation inhomo-
geneity [94]; decrease sputum markers of local inflamma-
tion [92,95]; reduce pulmonary exacerbation risk [33,35];
improve CF pulmonary function [33,35]; slow the rate of
at which pulmonary function is lost [96]; and improve sur-
vival [97]. It is generally well-tolerated and has become a
mainstay in the recommended treatments to maintain
lung health [98].
Aerosolized antibiotics
As stated earlier, there are several situations in which
antibiotics are used to treat CF airways disease. Chronic
prophylaxis primarily targets acquisition of Staphylococ-
cus aureus in infants by use of oral flucloxacillin [99], but
is used only regionally (primarily in the UK and Europe)
based upon local experience and tradition, the differential
weighting of apparently conflicting study results [99-101]
and drug availability. Newly detected Pseudomonas aeru-
ginosa from throat cultures has been treated with inhaled
antipseudomonal antibiotics [102-105] with or without
concomitant oral ciprofloxacin and intravenous antipseu-
domonal antibiotics. Although these interventions are
routinely capable of converting >80% of patients to
P. aeruginosa culture negativity [104,106-109], the ulti-
mate clinical benefit of delaying chronic P. aeruginosa
infection with this approach has not been robustly
demonstrated.
Ironically, the potentially most heretical use of antibio-
tics in CF, the chronic suppression of bacterial opportu-
nists in the airway without their eradication, is the one
with the greatest empirical evidence for clinical benefit.
Chronic or chronic intermittent administration of the
inhaled antipseudomonal antibiotics colistimethate,
tobramycin and aztreonam has been associated with
improved quality of life [110,111], decreased risk of
exacerbation [34,112], improved pulmonary function
[34,111], and decreased mortality [97]. This practice,
which has expanded substantially in recent decades [47],
was predated by scheduled, periodic treatment of patients
with intravenous antibiotics [113,114].
Anti-inflammatory medications
The inflammatory response in the airways of patients with
CF is excessive and it is thought that the inflammation
overwhelms the natural protective mechanisms of the air-
way [115]. It is the excessive and persistent inflammation
that is likely to be the main cause of destruction of the air-
ways over time, so it is logical that anti-inflammatory ther-
apy could provide benefit to the progression of CF airways
disease.
Chronic administration of oral prednisone has been
shown to improve pulmonary function in children with
CF [116] but also to result in significant growth impair-
ment [117] in a population with preexisting growth chal-
lenges. Inhaled corticosteroids may reduce the potential
for adverse effects, but the evidence for the benefit of
chronic inhalation of corticosteroids is conflicting
[98,118-120]. There has never been a randomized con-
trolled trial describing the treatment benefit of inhaled
corticosteroids, although a controlled study has demon-
strated that withdrawal of the inhaled corticosteroid fluti-
casone was not associated with an increased rate of
exacerbation or reduced pulmonary function during a six-
month post withdrawal period [118]. However, two retro-
spective CF registry analyses have independently shown an
association between chronic inhaled corticosteroid use
and a reduced rate of lung function decline over a period
of years [119,120], again suggesting that short-term mea-
sures of respiratory health may not be perfect surrogates
for longer-term disease progression. Current US chronic
respiratory therapy guidelines recommend against the use
of inhaled corticosteroids in patients without asthma [98],
although their use remains extremely common [47], per-
haps in part because of the very low treatment burden
associated with the administration of drug via a metered-
dose inhaler.
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As an alternative, nonsteroidal anti-inflammatory drugs
have been studied as a treatment of CF lung disease.
Ibuprofen, when taken in high doses, inhibits the migra-
tion, adherence and aggregation of neutrophils [121-123].
Despite prospective and retrospective demonstration that
chronic administration of high dose ibuprofen reduces the
rates of pulmonary function decline [124-126], less than
10% of eligible patients in the US receive this therapy
[1,47] due to concerns for rare, but very serious, gastric
bleeding associated with the treatment [124].
Macrolide antibiotics are currently recommended as a
chronic therapy for patients with CF to improve lung
function and reduce exacerbations [98], despite some
degree of uncertainty as to the exact mechanism(s) by
which macrolides exert their clinical effect. Although
azithromycin, the macrolide most commonly prescribed
to patients with CF, is marketed as an antibiotic, there is
substantial evidence that a reduction in airway inflamma-
tion plays a key role in its efficacy in CF. The clinical evi-
dence of a macrolide-derived anti-inflammatory effect
includes a decrease in the number of neutrophils present
at the site of infection [127-130] and a reduction in pro-
inflammatory cytokines that recruit more neutrophils
[131,132]. EM703, a macrolide variant with essentially no
antimicrobial activity [133], retains strong immunomodu-
latory properties and has been shown to protect against
chemically-induced pulmonary fibrosis in an animal
model [134]. Generally, macrolides such as azithromycin
are not considered to be effective against Pseudomonas
using traditional in vitro susceptibility testing for CF bac-
terial isolates, although reports of clinical benefit have
been derived from large studies in persons with CF and
chronic P. aeruginosa infection [135,136]. However,
in vitro studies have suggested that the clinical efficacy of
azithromycin may result directly from a cidal activity
against Pseudomonas [137,138] or indirectly by inhibition
of bacterial biofilm production [139,140]. Patients with
CF receiving chronic azithromycin have been shown to
culture strains of S. aureus and Haemophilus influenzae
with progressively reduced macrolide sensitivities over
time, indicative of an antibiotic effect, although not one
directed against Pseudomonas [141]. The question of
whether the macrolide benefit in CF results from either
direct suppression of inflammation or from an antimicro-
bial effect, or both, is of more than academic importance.
Presumably, individuals are less likely to become refrac-
tory to an anti-inflammatory effect with chronic expo-
sure, while the same may not be true for chronic
antibiotic exposure.
As stated earlier, the neutrophil-dominated inflamma-
tion in the airways overwhelms the natural protection,
notably the neutrophil elastase alpha1-antitrypsin (A1AT).
When given in aerosol form to 12 patients with CF, A1AT
suppressed neutrophil elastase in the respiratory ASL and
reversed the inhibitory effect of CF ASL on Pseudomonas-
killing by neutrophils [142]. Early studies of A1AT treat-
ment have demonstrated a decrease in inflammatory para-
meters after treatment [142,143]. The challenge to this
therapy is the ability to deliver an effective dose to the air-
ways. New technologies of aerosol devices may make this
therapy more viable.
Another observation in CF airways disease is that there
is a reduction in glutathione, an important component of
airway defense, in the lower airways as measured in
bronchoalveolar lavage fluid [144]. It has been suggested
that replacement of glutathione directly, or indirectly be
replacing sulfhydryl groups through administration of
N-acetyl cysteine (NAC) might reduce the inflammatory
response. A pilot study of inhaled glutathione in 19
patients with CF suggested a trend towards improved
inflammatory outcomes [145]. Early trials suggested that
high dose NAC might also reduce the inflammatory state,
but a single-center study failed to demonstrate a change in
clinical or inflammatory parameters in the bronchoalveo-
lar lavage fluid of patients [146]. Nonetheless, extracellular
glutathione in induced sputum tended to increase on
high-dose NAC, suggesting there was an effect on increas-
ing available glutathione. Whether enhancing airway glu-
tathione levels by either approach will improve CF lung
health remains to be demonstrated.
Lung transplantation
For those patients who progress to an advanced severity,
lung transplantation may be an option. In carefully
selected patients, lung transplantation has demonstrated
great success with a one-year survival of approximately
90%, but the five-year survival is only 50%, most likely
because of the development of chronic rejection as
bronchiolitis obliterans [147]. The etiology of chronic
rejection remains debated but a prime strategy of treating
it, or trying to prevent it, is chronic administration of anti-
rejection medications, such as cyclosporine A and tacroli-
mus [148]. A principal adverse event associated with long-
term immunosuppression is chronic renal insufficiency, a
complication that has led to the study of inhaled cyclos-
porine A (originally studied as a rescue medication for
acute transplant rejection [149]) as a topical alternative for
long-term immunosuppression to reduce systemic expo-
sure. A small single-center randomized controlled clinical
study suggested that treatment of lung transplant recipi-
ents with inhaled cyclosporine A beginning shortly after
transplant reduced chronic rejection and improved survi-
val while not increasing the risk of infection [149]. A large
multicenter controlled clinical trial of inhaled cyclosporine
(NCT00755781) has apparently completed enrollment, but
no results from this Phase III study have been released.
Flume and Van Devanter BMC Medicine 2012, 10:88
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Conclusions
The last two decades have seen a remarkable addition of
effective medications and therapies to the regimen for
treating CF lung disease. These therapies have improved
the overall health of patients with CF and they are clearly
part of the reason that expected survival has increased.
However, these therapies do not offer a cure and they
mainly treat downstream complications of the pathophy-
siology of CF lung disease, meaning that patients continue
to suffer the morbidity associated with chronic airways
infection and predicted survival still lags well below what
is normal. In addition, these therapies add to a consider-
able treatment burden and so are also associated with
poor adherence.
There are two main areas we need to focus on for there
to be further improvement. First, we must develop new,
more effective medications. Ideally, these would be direc-
ted at earlier events in the pathophysiology of disease,
such as seen with ivacaftor, and perhaps earlier use of
such medications would prevent, or at least delay, the
development of downstream events such as chronic infec-
tion of the airways. Another approach would be to change
the formulation of current medications to reduce the
treatment burden, and hopefully increase adherence to the
medication. An example is the development of a dry pow-
der to replace an aerosol medication, such as tobramycin
inhalation powder, which has been shown to be equivalent
to tobramycin inhalation solution in terms of efficacy, but
is associated with a markedly reduced treatment time and
greater patient satisfaction [150]. There is also a need for
the development of additional agents within the current
classes to enhance the treatment options should current
treatments seem to be less effective. An example is the
addition of a class of inhaled antibiotics. Currently we
have an aminoglycoside and a beta-lactam antibiotic
approved for aerosol use in CF, and a fluoroquinolone,
which is in the late stages of development [151], would
add to the treatment options.
Second, there must be optimization of the currently
available therapies. All of the existing therapies were devel-
oped compared to placebo and we have little information
about which combination of drugs is most effective. We
also do not know if there is a more effective order in
which to use the medications. Comparative effectiveness
research may be an effective method of identifying the
optimal treatment strategy for patients, perhaps allowing
elimination of some drugs for some patients, again redu-
cing the treatment burden. Not discussed here but also
very important is the development of new devices that are
intended to improve the delivery of drug to the lower air-
ways; these devices are more efficient and so can deliver
the needed dose in a much smaller volume and, therefore,
a much shorter time.
There are medications currently up for review by the
FDA, including mannitol and tobramycin inhalation
powder and another (levofloxacin inhalation solution)
that is very near completion of Phase III trials, meaning
the CF armamentarium could have as many as three new
weapons in the very near future. These will be important
options for our patients. However, it is the CFTR modu-
lators that have generated the most excitement. Although
they are not a cure, they represent our first successes at
treating early events in the pathophysiology of CF lung
disease, meaning they have real potential for being truly
disease modifying. Although the approval of ivacaftor
offers treatment to a minority of patients (<4%), the
demonstration that this strategy can work offers great
hope to the CF community. New medications will have
to be developed for each type of mutation and having
two new medications in active investigation for F508del,
by far the most common CFTR mutation, brings us that
much closer to making a huge difference in the lives of
our patients.
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